UNSPSC 51262908: Bopindolol

This classification denotes an adrenergic beta-antagonist with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KT304VZO57, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, benzoate (ester), (+-)- but generally known as bopindolol, which bears US NIH Compound Identifier 44112. Bopindolol most often comes in base and malonate forms.

UNSPSC 51262908 Bopindolol is a Commodity code that nominally designates a beta-blocker pharmaceutical, but the recent state and local procurement activity tagged under it does not reflect pharmaceutical inventory procurement. Instead, the single recent opportunity in the record shows Seminole County, Florida soliciting through an IFB for naloxone and safe drug deactivation systems — products unrelated to bopindolol itself. The mismatch suggests either a cataloging error in the state or local procurement system or a broad misapplication of the code to cover emergency-response and public-health supplies more generally. Based on available evidence, this code shows little relevant recent activity for vendors supplying bopindolol or similar beta-blockers to state and local buyers.

Seminole County's IFB 60459723LAS (due July 26, 2023, though posted June 30, 2026 per the record metadata) sought annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with one-year renewal option, fixed-fee pricing, and potential FEMA funding, with standard compliance requirements including E-Verify, workers' compensation insurance, and drug-free workplace certification. The scope emphasizes that vendors must include all shipping and delivery costs in their proposals and submit bids electronically through the county's e-Procurement Portal. No explicit set-aside designations were noted. Without additional opportunities matching the code's nominal pharmaceutical scope, pursuit of this Commodity code appears low-priority for suppliers of bopindolol or related cardiovascular products.